ISIN | LU2289394632 |
---|---|
Valor Number | 59412744 |
Bloomberg Global ID | |
Fund Name | UBS (Lux) Digital Health Equity Fund IBH |
Fund Provider |
Credit Suisse Fund Management S.A.
Zürich, Switzerland Phone: +41 44 333 40 50 E-Mail: clientservices.amfunds@credit-suisse.com Web: www.credit-suisse.com |
Fund Provider | Credit Suisse Fund Management S.A. |
Representative in Switzerland |
UBS Fund Management (Switzerland) AG Basel Phone: +41 61 288 49 10 |
Distributor(s) |
UBS AG Basel Phone: +41 61 288 75 01 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The objective of the Subfund is to achieve the highest possible return in US dollars (Reference Currency), while taking due account of the principle of risk diversification, the security of the capital invested, and the liquidity of the assets. This Subfund aims to outperform the return of the MSCI World ESG Leaders (NR) benchmark. The Subfund is actively managed. The benchmark is used as a reference point for portfolio construction and as a basis for setting risk constraints, and/or for Performance Fee measurement purposes. The majority of the Subfund’s equity securities will not necessarily be components of or have weightings derived from the benchmark. The Investment Manager will use its discretion to significantly deviate the weighting of certain components of the benchmark and to significantly invest in companies or sectors not included in the benchmark in order to take advantage of specific investment opportunities. |
Peculiarities |
Current Price * | 521.00 GBP | 02.12.2024 |
---|---|---|
Previous Price * | 514.13 GBP | 29.11.2024 |
52 Week High * | 530.80 GBP | 27.02.2024 |
52 Week Low * | 438.83 GBP | 05.12.2023 |
NAV * | 521.00 GBP | 02.12.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 812,082,959 | |
Unit/Share Assets *** | 1,067,869 | |
Trading Information SIX |
YTD Performance | +3.65% |
29.12.2023 - 02.12.2024
29.12.2023 02.12.2024 |
---|---|---|
YTD Performance (in CHF) | +8.60% |
29.12.2023 - 02.12.2024
29.12.2023 02.12.2024 |
1 month | +6.65% |
04.11.2024 - 02.12.2024
04.11.2024 02.12.2024 |
3 months | +7.25% |
03.09.2024 - 02.12.2024
03.09.2024 02.12.2024 |
6 months | +13.92% |
03.06.2024 - 02.12.2024
03.06.2024 02.12.2024 |
1 year | +15.99% |
04.12.2023 - 02.12.2024
04.12.2023 02.12.2024 |
2 years | +1.25% |
02.12.2022 - 02.12.2024
02.12.2022 02.12.2024 |
3 years | -31.71% |
02.12.2021 - 02.12.2024
02.12.2021 02.12.2024 |
5 years | -47.90% |
29.01.2021 - 02.12.2024
29.01.2021 02.12.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Natera Inc | 4.14% | |
---|---|---|
Veeva Systems Inc Class A | 3.95% | |
Zai Lab Ltd Ordinary Shares | 3.91% | |
Schrodinger Inc Ordinary Shares | 3.83% | |
MEDLEY Inc Ordinary Shares | 3.78% | |
TransMedics Group Inc | 3.74% | |
Redcare Pharmacy NV | 3.73% | |
Zealand Pharma AS | 3.71% | |
Exact Sciences Corp | 3.61% | |
Krystal Biotech Inc | 3.54% | |
Last data update | 30.11.2024 |
TER | 1.24% |
---|---|
TER date | 31.05.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.90% |
Ongoing Charges *** | 1.24% |
SRRI ***
|
|
SRRI date *** |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |